Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen, compared with those who remained on tamoxifen for the entire 5 years of endocrine therapy.
LISTEN
[audio:https://www.audiomedica.com/podcasting/otbn/090924OTBNCharlesCoombesPODCAST.mp3]
The microbiome is emerging as a powerful ally to cancer doctors to harness in tandem with curative therapies, especially with allogeneic stem cell...
Bi-specific T-cell engager promise in B-cell acute lymphoblastic leukemia
Single cell transcriptome analysis yields details of molecular features that promise to help customise therapy for each individual patient.
Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant...
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Audio Journal of Oncology Podcast CT Screening Cuts Lung Cancer Deaths 24-Per Cent Second Study Confirms Play Episode Pause Episode 1x 00:00 / 20...
